The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
Open accessAbstract
Significance: Dimethyl fumarate (DMF) (BG-12, Tecfidera), a fumaric acid ester (FAE), is a commonly prescribed oral therapy for multiple sclerosis (MS), a CNS autoimmune inflammatory demyelinating disease that may result in sustained neurologic damage. It is thought that the benefit of DMF in MS therapy is mediated through activation of the antioxidative transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway. However, the role of Nrf2 in the antiinflammatory effects of DMF has not been fully elucidated. Here, we investigated the role of Nrf2 in DMF treatment of the MS model, experimental autoimmune encephalomyelitis (EAE), and demonstrated DMF can modulate T cells, B cells, and antigen-presenting cells, and reduce clinical and histologic EAE, independent of Nrf2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999 · cited 2×
“Upon FAE conjugation to Keap1, Nrf2 is released, permitting nuclear translocation and initiation of gene transcription (5, 6, 24).”
BackgroundCell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630
Targeting the KEAP1-NRF2 system to prevent kidney disease progression
Nezu, M., Suzuki, N., & Yamamoto, M. (2017) · American Journal of Nephrology · doi:10.1159/000475890 · Cited by 3,447
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Kuchroo, V. K., Prabhu Das, M., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N., & Glimcher, L. H. (1995) · Cell · doi:10.1016/0092-8674(95)90349-6 · Cited by 1,641
Self-citationPlacebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Self-citationNrf2 is a critical regulator of the innate immune response and survival during experimental sepsis
Thimmulappa, R. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25790 · Cited by 1,028 · cited 1×
“Consistent with these observations, results indicate Nrf2 itself may regulate innate and adaptive T-cell immune responses in models of organ-specific inflammation (12, 13), including EAE (14, 15).”
ResultBettelli, E., Pagany, M., Weiner, H. L., Linington, C., Sobel, R. A., & Kuchroo, V. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021603 · Cited by 825
Self-citationItoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., O'Connor, T., & Yamamoto, M. (2003) · Genes to Cells · doi:10.1046/j.1365-2443.2003.00640.x · Cited by 816
Kappos, L., Gold, R., Miller, D. H., MacManus, D. G., Havrdova, E., Limmroth, V., Polman, C. H., Schmierer, K., Yousry, T. A., Yang, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61619-0 · Cited by 482
Scannevin, R. H., Chollate, S., Jung, M.-Y., Shackett, M., Patel, H., Bista, P., Zeng, W., Ryan, S., Yamamoto, M., Lukashev, M., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.190132 · Cited by 461
Self-citationType II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447
Self-citationMolnarfi, N., Schulze-Topphoff, U., Weber, M. S., Patarroyo, J. C., Prod’homme, T., Varrin-Doyer, M., Shetty, A., Linington, C., Slavin, A. J., Hidalgo, J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130699 · Cited by 418
Self-citationCD11b+Ly-6Chi Suppressive Monocytes in Experimental Autoimmune Encephalomyelitis
Zhu, B., Bando, Y., Xiao, S., Yang, K., Anderson, A. C., Kuchroo, V. K., & Khoury, S. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5228 · Cited by 370
Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide
Thimmulappa, R. K., Scollick, C., Traore, K., Yates, M., Trush, M. A., Liby, K. T., Sporn, M. B., Yamamoto, M., Kensler, T. W., & Biswal, S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.102 · Cited by 357
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
Ghoreschi, K., Brück, J., Kellerer, C., Deng, C., Peng, H., Rothfuss, O., Hussain, R. Z., Gocke, A. R., Respa, A., Glocova, I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100977 · Cited by 352
Nguyen, T., Sherratt, P. J., Nioi, P., Yang, C. S., & Pickett, C. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503074200 · Cited by 344
Bettelli, E., Baeten, D., Jäger, A., Sobel, R. A., & Kuchroo, V. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28334 · Cited by 336
Self-citationKrishnamoorthy, G., Lassmann, H., Wekerle, H., & Holz, A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28330 · Cited by 335
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
Chen, H., Assmann, J. C., Krenz, A., Rahman, M., Grimm, M., Karsten, C. M., Köhl, J., Offermanns, S., Wettschureck, N., & Schwaninger, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72151 · Cited by 297
Aharoni, R., Teitelbaum, D., Sela, M., & Arnon, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10821 · Cited by 274
Litzenburger, T., Fässler, R., Bauer, J., Lassmann, H., Linington, C., Wekerle, H., & Iglesias, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.1.169 · Cited by 256
Dimethylfumarate for psoriasis: more than a dietary curiosity
MROWIETZ, U., & ASADULLAH, K. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.11.003 · Cited by 206
Johnson, D. A., Amirahmadi, S., Ward, C., Fabry, Z., & Johnson, J. A. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfp274 · Cited by 203
Nrf2 regulates haematopoietic stem cell function
Tsai, J. J., Dudakov, J. A., Takahashi, K., Shieh, J.-H., Velardi, E., Holland, A. M., Singer, N. V., West, M. L., Smith, O. M., Young, L. F., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2699 · Cited by 202
Parodi, B., Rossi, S., Morando, S., Cordano, C., Bragoni, A., Motta, C., Usai, C., Wipke, B. T., Scannevin, R. H., Mancardi, G. L., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1422-3 · Cited by 194
Self-citationBrennan, M. S., Matos, M. F., Li, B., Hronowski, X., Gao, B., Juhasz, P., Rhodes, K. J., & Scannevin, R. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120254 · Cited by 188 · cited 8×
“Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway.”
BackgroundInfluentialSelf-citationReduction of CD8 + T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
Spencer, C. M., Crabtree-Hartman, E. C., Lehmann-Horn, K., Cree, B. A. C., & Zamvil, S. S. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000076 · Cited by 187
Self-citationMouse models for multiple sclerosis: Historical facts and future implications
Croxford, A. L., Kurschus, F. C., & Waisman, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.010 · Cited by 181
DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner
Gillard, G. O., Collette, B., Anderson, J., Chao, J., Scannevin, R. H., Huss, D. J., & Fontenot, J. D. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.006 · Cited by 173
Self-citationLehmann, J. C. U., Listopad, J. J., Rentzsch, C. U., Igney, F. H., von Bonin, A., Hennekes, H. H., Asadullah, K., & Docke, W.-D. F. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700686 · Cited by 158
Th2 Skewing by Activation of Nrf2 in CD4+ T Cells
Rockwell, C. E., Zhang, M., Fields, P. E., & Klaassen, C. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101712 · Cited by 142
The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist
Tang, H. L., Lu, J. Y.-L., Zheng, X., Yang, Y., & Reagan, J. D. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.041 · Cited by 134
Schulze-Topphoff, U., Prat, A., Prozorovski, T., Siffrin, V., Paterka, M., Herz, J., Bendix, I., Ifergan, I., Schadock, I., Mori, M. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1980 · Cited by 131
Self-citationDimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
Longbrake, E. E., Ramsbottom, M. J., Cantoni, C., Ghezzi, L., Cross, A. H., & Piccio, L. M. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515608961 · Cited by 120
Therapeutic Decisions in Multiple Sclerosis: Moving Beyond Efficacy
Brück, W., Gold, R., Lund, B. T., Oreja‐Guevara, C., Prat, A., Spencer, C. M., Steinman, L., Tintoré, M., Vollmer, T. L., Weber, M. S., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3510 · Cited by 112
Self-citationStüve, O. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25805 · Cited by 107
Cell type-specific Nrf2 expression in multiple sclerosis lesions
Licht‐Mayer, S., Wimmer, I., Traffehn, S., Metz, I., Brück, W., Bauer, J., Bradl, M., & Lassmann, H. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1452-x · Cited by 93
Sheikh, S. I., Nestorov, I. A., Russell, H. K., O'Gorman, J. T., Huang, R., Milne, G. L., Scannevin, R. H., Novas, M., & Dawson, K. T. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.009 · Cited by 61
Self-citationGlial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and Psoriasis
Metz, I., Traffehn, S., Straßburger-Krogias, K., Keyvani, K., Bergmann, M., Nolte, K. W., Weber, M. S., Bartsch, T., Gold, R., & Brück, W. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000099 · Cited by 21
Effects of glatiramer acetate in a spontaneous model of autoimmune neuroinflammation.
Bittner, S., Ruck, T., Göbel, K., Henschel, C. M., Afzali, A., Göb, E., Müntefering, T., Kleinschnitz, C., Wiendl, H., & Meuth, S. (2014) · American Journal of Pathology · doi:10.1016/j.ajpath.2014.03.009 · Cited by 10
Cited by
Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity
Kornberg, M. D., Bhargava, P., Kim, P. M., Putluri, V., Snowman, A. M., Putluri, N., Calabresi, P. A., & Snyder, S. H. (2018) · Science · doi:10.1126/science.aan4665 · Cited by 687
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
“Therefore, upregulation of NRF2 represents a mechanism of adaptation of cancer cells to tolerate high ROS levels that propel tumor progression (Schumacker, 2006) as well as to maintain cancer stem cells that are responsible for tumor relapse and formation of distant metastases (Ryoo et al., 2016).”
BackgroundUnderstanding mechanisms of antioxidant action in health and disease
Halliwell, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00645-4 · Cited by 629
Targeting immunometabolism as an anti-inflammatory strategy
Pålsson-McDermott, E. M., & O’Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 577
Modulating NRF2 in Disease: Timing Is Everything
Dodson, M., de la Vega, M. R., Cholanians, A. B., Schmidlin, C. J., Chapman, E., & Zhang, D. D. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021856 · Cited by 522
Metadata
- Authors
- Schulze-Topphoff, U., Varrin-Doyer, M., Pekarek, K., Spencer, C. M., Shetty, A., Sagan, S. A., Cree, B. A. C., Sobel, R. A., Wipke, B. T., Steinman, L., Scannevin, R. H., & Zamvil, S. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-04-13
- Volume
- 113
- Issue
- 17
- Pages
- 4777-4782
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2336862132
- Cited by
- 293
- References
- 43
- FWCI
- 28.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.